Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Exenatide: Brand names Byetta, Bydureon, and Exenatide Byetta, Byduren: Same as above
Quick Takeaways Retatrutide is a triple-receptor agonist (GLP-1, GIP, glucagon) delivering superior monotherapy weight loss at 2428.7% over 4868 weeks Cagrilintide targets amylin receptors for satiety and gastric emptying, achieving 10.8% weight loss in 26 weeks as a monotherapy Retatrutide provides broader metabolic benefits, including dramatic improvements in HbA1c, blood pressure, waist circumference, insulin sensitivity, and liver fat normalization No head-to-head trials exist yet, but the mechanistic and clinical data strongly favor Retatrutide for total body recomposition Retatrutide vs Cagrilintide: Side-by-Side Comparison What Makes Retatrutide Different Retatrutide isnt just another GLP-1 receptor agonist
Richard Sadove is a board-certified plastic surgeon with over 35 years of experience
Retatrutide: A triple agonist hitting GLP-1, GIP, and glucagon receptors
N.PickenhagenA.LindholmJ.TiraboschiE.KulesskayaN.AgustsdottirA.et al
Park H, Oh J, Shim G, Cho B, Chang Y, Kim S, Baek S, Kim H, Shin J, Choi H, et al
